Table 3 Baseline characteristics in individuals with NGT, PRED, T1D and T2D.
From: Cohort profile of the Heidelberg study on diabetes and complications HEIST-DiC
NGT | PRED | T1D | T2D | |
|---|---|---|---|---|
Age <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–80 >80 | 0 2.9 5.9 4.4 5.9 8.8 13.2 10.3 22.1 10.3 10.3 4.4 1.5 0 | 0 0 0 2.5 3.4 3.4 9.2 20.2 19.3 18.5 15.1 5.0 2.5 0.8 | 3.6 8.4 10.8 9.6 9.6 3.6 4.8 7.2 15.7 9.6 8.4 4.8 2.4 1.2 | 0 0 0.4 0 2.8 2.8 6.0 9.6 11.0 19.5 19.5 18.8 9.2 0.4 |
Sex Male Female | 30.9 69.1 | 52.1 47.9 | 50.6 49.4 | 59.9 40.1 |
Diabetes duration <1 1–5 6–10 11–15 16–20 21–25 26–30 31–35 36–40 41–45 46–50 51–55 56–60 61–65 >66 | NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA | NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA | 10.8 13.3 4.8 13.3 10.8 10.8 6.0 9.6 6.0 2.4 4.8 2.4 2.4 1.2 1.2 | 12.1 24.1 20.6 16.7 16.0 5.3 3.2 1.1 0.7 0.4 0 0 0 0 0 |
Family history of diabetes Siblings Father Mother Grandparents (father side) Grandparents (mother side) | 13.2 16.2 25.0 4.4 13.2 | 11.8 19.3 23.5 6.7 15.1 | 9.6 6.0 12.1 13.3 21.7 | 24.5 29.1 32.3 9.9 14.2 |
Other diseases Hypertension History of myocardial infarction Coronary heart disease Current smoking Lung diseases Diabetic retinopathy Diabetic nephropathy Diabetic neuropathy | 17.7 0 2.9 10.3 16.2 0 0 0 | 43.7 5.9 7.6 8.4 16.0 0 0 1.7 | 49.4 6.0 7.2 16.9 9.6 6.0 21.7 28.9 | 77.0 7.1 16.7 12.8 19.9 11.0 8.9 47.2 |
Glucose lowering therapy Insulin (short acting) Insulin (long acting) Insulin (mixed) Metformin Acarbose Sulfonylurea Glinide Dipeptidyl-peptidase-4 inhibitors PPAR agonists GLP-1 agonists SGLT-2 inhibitors | 0 0 0 2.9 0 0 0 0 0 0 0 | 0 0 0 0.8 0 0 0 0 0 0 0 | 97.6 72.3 1.2 4.8 0 0 0 0 0 0 2.4 | 18.8 25.9 1.1 62.4 0.4 4.3 1.1 20.6 0.7 6.4 16.7 |
Antihypertensive therapy Blockers of the renin-angiotensin system Beta blockers Calcium channel blockers Alpha1 inhibitors Alpha2 agonists Diuretics | 13.2 7.4 4.4 1.5 0 4.4 | 35.3 19.3 13.5 3.4 0 11.8 | 33.7 18.1 14.5 4.8 0 12.1 | 61.0 34.4 22.7 7.5 3.6 33.0 |
Other therapies Acetylsalicylic acid Statins Clopidogrel Tricyclic antidepressants Anticonvulsants Inhaled anticholinergics Inhaled beta2 agonists Inhaled corticoids L-Thyroxin | 8.8 5.9 0 0 1.5 1.5 2.9 2.9 16.2 | 9.2 16.8 0 1.7 0.8 1.7 6.7 4.2 24.4 | 19.3 27.7 0 1.2 3.6 0 2.4 1.2 24.1 | 30.1 45.0 2.1 4.3 9.9 1.4 4.3 2.5 24.5 |
Cardiovascular risk (ESC-Score 2) low to moderate high very high | 51.9 36.5 11.5 | 31.2 45.0 23.9 | 27.3 34.1 38.6 | 14.3 50.8 34.9 |
